Home › Compare › GHIFF vs ABBV
GHIFF yields 4.48% · ABBV yields 3.06%● Live data
📍 GHIFF pulled ahead of the other in Year 1
Combined, GHIFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GHIFF + ABBV for your $10,000?
Gamehost Inc., together with its subsidiaries, operates hospitality and gaming properties in Alberta. The company operates through Gaming, Hotel, and Food and Beverage segments. Its gaming activities include the operation of company owned table games and government owned slot machines, video lottery terminals, and lottery ticket kiosks, as well as the provision of food, beverage, and entertainment services; and hotel activities comprise the operation of full and limited service hotels, and the provision of banquet and convention services. The company owns and operates the Rivers Casino, a 33,314 square foot casino and entertainment facility located in Grande Prairie; the Boomtown Casino, a 27,976 square foot casino and entertainment facility located in Fort McMurray; and the Service Plus Inns & Suites, Encore Suites, and limited service hotels in Grande Prairie. It also owns a 10,530 square-foot commercial multi-tenant lease facility in Grande Prairie; and a 91% interest in the Deerfoot Inn & Casino joint venture, which owns and operates the Deerfoot Inn & Casino, a full-service convention, entertainment, and casino facility in south-east Calgary, Alberta. Gamehost Inc.was founded in 2003 and is headquartered in Red Deer County, Canada.
Full GHIFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.